Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ. Tambyah PA, et al. Among authors: van der velden m. Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22080174 Clinical Trial.
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P. Ehrlich HJ, et al. Among authors: van der velden mv. J Infect Dis. 2009 Oct 1;200(7):1113-8. doi: 10.1086/605608. J Infect Dis. 2009. PMID: 19712040 Clinical Trial.
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. van der Velden MV, et al. Vaccine. 2012 Sep 21;30(43):6127-35. doi: 10.1016/j.vaccine.2012.07.077. Epub 2012 Aug 8. Vaccine. 2012. PMID: 22884662 Clinical Trial.
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.
van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G. van der Velden MV, et al. J Infect Dis. 2014 Jan 1;209(1):12-23. doi: 10.1093/infdis/jit498. Epub 2013 Sep 16. J Infect Dis. 2014. PMID: 24041789 Clinical Trial.
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, Zeitlinger M, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G. van der Velden MV, et al. Clin Vaccine Immunol. 2014 Jun;21(6):867-76. doi: 10.1128/CVI.00065-14. Epub 2014 Apr 16. Clin Vaccine Immunol. 2014. PMID: 24739978 Free PMC article. Clinical Trial.
Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Aichinger G, Grohmann-Izay B, van der Velden MV, Fritsch S, Koska M, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN. Aichinger G, et al. Among authors: van der velden mv. Clin Vaccine Immunol. 2015 Jan;22(1):46-55. doi: 10.1128/CVI.00275-14. Epub 2014 Oct 29. Clin Vaccine Immunol. 2015. PMID: 25355797 Free PMC article. Clinical Trial.
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.
Wressnigg N, van der Velden MV, Portsmouth D, Draxler W, O'Rourke M, Richmond P, Hall S, McBride WJ, Redfern A, Aaskov J, Barrett PN, Aichinger G. Wressnigg N, et al. Among authors: van der velden mv. Clin Vaccine Immunol. 2015 Mar;22(3):267-73. doi: 10.1128/CVI.00546-14. Epub 2014 Dec 24. Clin Vaccine Immunol. 2015. PMID: 25540268 Free PMC article. Clinical Trial.
Course of pandemic influenza A(H1N1) 2009 virus infection in Dutch patients.
Friesema IH, Meijer A, van Gageldonk-Lafeber AB, van der Lubben M, van Beek J, Donker GA, Prins JM, de Jong MD, Boskamp S, Isken LD, Koopmans MP, van der Sande MA; Dutch ZonMw Influenza A(H1N1) 2009 consortium. Friesema IH, et al. Influenza Other Respir Viruses. 2012 May;6(3):e16-20. doi: 10.1111/j.1750-2659.2012.00347.x. Epub 2012 Feb 28. Influenza Other Respir Viruses. 2012. PMID: 22372759 Free PMC article.
Heart failure in nursing homes: A scoping review of educational interventions for optimising care provision.
McMahon J, Thompson DR, Cameron J, Wilson CB, Hill L, Tierney P, Yu D, Moser DK, Spilsbury K, Srisuk N, Schols JMGA, van der Velden M, Mitchell G. McMahon J, et al. Among authors: van der velden m. Int J Nurs Stud Adv. 2024 Jan 13;6:100178. doi: 10.1016/j.ijnsa.2024.100178. eCollection 2024 Jun. Int J Nurs Stud Adv. 2024. PMID: 38746815 Free PMC article. Review.
96 results